Volume 8 Issue 2-3
Oct.  2020
Turn off MathJax
Article Contents
Lei TANG, Hua-dan XUE, Zheng-yu JIN. Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy: Current Status and Prospect[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 82-89. doi: 10.3969/j.issn.1674-9081.2017.03.001
Citation: Lei TANG, Hua-dan XUE, Zheng-yu JIN. Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy: Current Status and Prospect[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 82-89. doi: 10.3969/j.issn.1674-9081.2017.03.001

Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy: Current Status and Prospect

doi: 10.3969/j.issn.1674-9081.2017.03.001
More Information
  • Corresponding author: JIN Zheng-yu  Tel:010-69155442, Email:jin_zhengyu@163.com.cn
  • Received Date: 2017-05-06
  • Publish Date: 2020-10-30
  • Targeted therapy is an important component of the individualized precision medical treatment for abdominal tumors. It is especially effective in the treatment of gastrointestinal stromal tumors, which is regarded as "a model of modern anti-cancer therapy". Radiology is the common method to evaluate the response of abdominal tumors to targeted therapy. The morphological bias is demonstrated in response evaluation criteria in solid tumors (RECIST) because of the diverse change of post-treatment tumor tissue. The problem of enlarged tumor caused by necrosis and cystic degeneration was resolved by combination of Choi, mChoi, size and morphology(SACT), morphology, attenuation, size and structure(MASS), and CT values. The new technologies of positron emission tomography (PET), diffusion-weighted imaging (DWI), dynamic contrast enhanced magneticresonance imaging(DCE-MRI) and monochromatic CT, and a series of functional imaging parameters including standard uptake value (SUV), apparent diffusion coefficient (ADC), Ktrans value and iodine concentration, provide potential surrogate for the prediction and early evaluation of tumors to targeted therapy. Texture analysis technique in radiology can further explore the radiological information, to provide rich quantitative parameters for response evaluation. The radiologists should strengthen the communication with clinicians and initiate cooperative research through multi-disciplinary team (MDT) patterns, actively explore new parameters and criteria to further improve the response prediction and evaluation of targeted therapy for abdominal tumors.

  • loading
  • [1] 冯睿, 张小田, 杨升.胃癌靶向治疗的研究现状与进展[J].中华胃肠外科杂志, 2016, 19:1191-1196. doi:  10.3760/cma.j.issn.1671-0274.2016.10.027
    [2] Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour[J]. Lancet, 2007, 369:1731-1741. doi:  10.1016/S0140-6736(07)60780-6
    [3] Von Mehren M, Randall RL, Benjamin RS, et al. Gastrointestinal stromal tumors, version 2[J]. J Natl Compr Canc Netw, 2014, 12:853-862. doi:  10.6004/jnccn.2014.0080
    [4] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45:228-247. doi:  10.1016/j.ejca.2008.10.026
    [5] Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:proposal of new computed tomography response criteria[J]. J Clin Oncol, 2007, 25:1753-1759. doi:  10.1200/JCO.2006.07.3049
    [6] 唐磊, 孙应实, 沈琳, 等.胃肠间质瘤靶向治疗CT征象演变及其与预后的关系[J].中华胃肠外科杂志, 2010, 13:497-501. doi:  10.3760/cma.j.issn.1671-0274.2010.07.009
    [7] 张晓鹏, 唐磊, 沈琳, 等.伊马替尼治疗胃肠间质瘤早期疗效评价研究[J].中国实用外科杂志, 2008, 28:1059-1062
    [8] Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35:421-430. doi:  10.1016/S0168-8278(01)00130-1
    [9] Kudo M, Ueshima K, Kubo S, et al. Response evaluation criteria in cancer of the liver (RECICL) (2015 Revised version)[J]. Kanzo, 2016, 46:261-266. doi:  10.1111/hepr.12542/pdf
    [10] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30:52. doi:  10.1055/s-0030-1247132
    [11] Tacher V, Lin M, Duran R, et al. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach[J]. Radiology, 2016, 278:275-284. doi:  10.1148/radiol.2015142951
    [12] Nathan PD, Vinayan A, Stott D, et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies[J]. Cancer Biol Ther, 2010, 9:15-19. doi:  10.4161/cbt.9.1.10340
    [13] Smith AD, Lieber ML, Shah SN.Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy:importance of size and attenuation on contrast-enhanced CT[J]. Am J Roentgenol, 2010, 194:157-165. doi:  10.2214/AJR.09.2941
    [14] Smith AD, Shah SN, Rini BI, et al. Morphology, Attenuation, Size, and Structure (MASS) criteria:assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy[J]. Am J Roentgenol, 2010, 194:1470-1478. doi:  10.2214/AJR.09.3456
    [15] Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy:comparison of RECIST, Choi and volumetric criteria[J].Eur J Radiol, 2013, 82:951-958.
    [16] Shinagare AB, Jagannathan JP, Kurra V, et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib[J]. Eur J Cancer, 2014, 50:981-986. doi:  10.1016/j.ejca.2013.11.037
    [17] Nakaigawa N, Kondo K, Tateishi U, et al. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies:max SUVmax predicts survival of patients with advanced renal cell carcinoma[J]. BMC Cancer, 2016, 16:67. doi:  10.1186/s12885-016-2097-4
    [18] Woff E, Hendlisz A, Garcia C. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43:1-10. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=767de36efefad1161ae1052d44049afc
    [19] Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours:best monitored with FDG PET[J]. Nucl Med Commun, 2004, 25:433-438. doi:  10.1097/00006231-200405000-00002
    [20] Shinto A, Nair N, Dutt A, et al.Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib[J].Clin Nucl Med, 2008, 33:486-487. doi:  10.1097/RLU.0b013e31817792a3
    [21] García-González J, Sánchez Salmón A, Areses Manrique C, et al. Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors[J]. Rev Esp Med Nucl, 2007, 26:100-102. doi:  10.1157/13099949
    [22] Tang L, Zhang XP, Sun YS, et al. Gastrointestinal stromal tumors treated with imatinib mesylate:apparent diffusion coefficient in the evaluation of therapy response in patients[J]. Radiology, 2011, 258:729-738. doi:  10.1148/radiol.10100402
    [23] Wong CS, Gong N, Chu YC, et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients:ADC versus SUV[J]. Eur J Radiol, 2012, 81:2122-2126. doi:  10.1016/j.ejrad.2011.09.003
    [24] Gong NJ, Wong CS, Chu YC, et al. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging:preliminary results in comparison with positron emission tomography/computed tomography[J]. NMR Biomed, 2013, 26:185-192. doi:  10.1002/nbm.2834
    [25] Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment:initial results[J]. Am J Roentgenol, 2009, 193:301-307. doi:  10.2214/AJR.08.2289
    [26] Jeon TY, Kim CK, Kim JH, et al. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging[J]. Br J Radiol, 2015, 88:20150163. doi:  10.1259/bjr.20150163
    [27] Granata V, Fusco R, Catalano O, et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs:the role of intravoxel incoherent mMotion in diffusion-weighted Imaging[J]. PloS One, 2015, 10:1-11.
    [28] Chen X, Ma Z, Huang Y, et al. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts[J]. J Magn Reson Imaging, 2016, doi:10.1002/jmri.25527.[Epub ahead of print]
    [29] Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI[J]. J Magn Reson Imaging, 2012, 35:745-763. doi:  10.1002/jmri.22838
    [30] Kim H, Keene KS, Sarver DB, et al. Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors:a pilot study[J]. Gastrointest Cancer Res, 2014, 7:75-81. http://www.ncbi.nlm.nih.gov/pubmed/25276260
    [31] Sahani DV, Jiang T, Koichi H, et al. Magnetic resonance imaging biomarkers in hepatocellular carcinoma:association with response and circulating biomarkers after sunitinib therapy[J]. J Hematol Oncol, 2013, 6:51. doi:  10.1186/1756-8722-6-51
    [32] Jeon TY, Kim CK, Kim JH, et al. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging[J]. Br J Radiol, 2015, 88:1766-1775. doi:  10.1259/bjr.20150163
    [33] Tang L, Li ZY, Li ZW, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT:a comparison with pathological regression[J]. Clin Radiol, 2015, 70:1198-1204. doi:  10.1016/j.crad.2015.06.083
    [34] Zhang LJ, Wu S, Wang M, et al. Quantitative dual energy CT measurements in rabbit VX2 liver tumors:Comparison to perfusion CT measurements and histopathological findings[J]. Eur J Radiol, 2012, 81:1766-1775. doi:  10.1016/j.ejrad.2011.06.057
    [35] Meyer M, Hohenberger P, Apfaltrer P, et al. CT-based response assessment of advanced gastrointestinal stromal tumor:dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria[J]. Eur J Radiol, 2013, 82:923-928. doi:  10.1016/j.ejrad.2013.01.006
    [36] Dai X, Schlemmer HP, Schmidt B, et al. Quantitative therapy response assessment by volumetric iodine-uptake measurement:initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Eur J Radiol, 2013, 82:327-334. doi:  10.1016/j.ejrad.2012.11.013
    [37] Hellbach K, Sterzik A, Sommer W, et al. Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer[J]. Eur Radiol, 2016:1-6. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=431147125bb334205ee9cdde2b760c52
    [38] Gillies RJ, Kinahan PE, Hricak H. Radiomics:images are more than pictures, they are data[J]. Radiology, 2015, 278:1511-1569. http://www.ncbi.nlm.nih.gov/pubmed/26579733
    [39] Sala E, Mema E, Himoto Y, et al. Unravellingtumour heterogeneity using next-generation imaging:radiomics, radiogenomics, and habitat imaging[J]. Clin Radiol, 2017, 72:3-10. doi:  10.1016/j.crad.2016.09.013
    [40] Goh V, Ganeshan B, Nathan P, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer:CT texture as a predictive biomarker[J]. Radiology, 2011, 261:165-171. doi:  10.1148/radiol.11110264
    [41] Kickingereder P, Götz M, Wick A, et al. Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response[J]. Clin Cancer Res, 2016, 22:5765-5771. doi:  10.1158/1078-0432.CCR-16-0702
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Article Metrics

    Article views (256) PDF downloads(10) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return